Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

The FDA is changing protocols to prevent contamination of fresh and frozen berries with enteric viruses such as norovirus and ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent ...

Patient monitors, used in both healthcare facilities and home settings, display vital patient information including ...

Domestic formulation sales increased by 13.8 per cent to Rs 4,300.4 crore Y-o-Y, representing 32 per cent of the company's ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...